Researchers said a fresh examination showed a malformation on a Centrosaurus was a manifestation of osteosarcoma, an aggressive bone cancer, making this the first known example of a dinosaur afflicted by malignant cancer.
Epizyme’s oral potent, first-in-class EZH2 inhibitor tazemetostat won accelerated approval from the U.S. Food and Drug Administration for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.